CINECA IRIS Institutional Research Information System

PELLEGRINI, CAROLINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.851
EU - Europa 2.125
AS - Asia 1.078
AF - Africa 116
SA - Sud America 43
OC - Oceania 2
Totale 7.215
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.787
IT - Italia 1.166
CN - Cina 592
SE - Svezia 271
SG - Singapore 226
BG - Bulgaria 162
DE - Germania 111
VN - Vietnam 89
GB - Regno Unito 82
RU - Federazione Russa 73
CI - Costa d'Avorio 65
AT - Austria 61
CA - Canada 55
FI - Finlandia 52
TR - Turchia 39
BR - Brasile 38
HK - Hong Kong 35
SN - Senegal 34
IN - India 32
FR - Francia 30
PL - Polonia 30
IR - Iran 21
UA - Ucraina 15
JP - Giappone 14
CZ - Repubblica Ceca 13
NL - Olanda 13
BE - Belgio 11
CH - Svizzera 11
KR - Corea 7
MX - Messico 7
NG - Nigeria 6
ES - Italia 5
PK - Pakistan 5
GH - Ghana 3
IE - Irlanda 3
LB - Libano 3
LT - Lituania 3
PT - Portogallo 3
RO - Romania 3
AU - Australia 2
AZ - Azerbaigian 2
BJ - Benin 2
DK - Danimarca 2
HU - Ungheria 2
MO - Macao, regione amministrativa speciale della Cina 2
NO - Norvegia 2
PH - Filippine 2
PY - Paraguay 2
SA - Arabia Saudita 2
UG - Uganda 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
CL - Cile 1
CO - Colombia 1
CU - Cuba 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
ID - Indonesia 1
JM - Giamaica 1
KG - Kirghizistan 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
TH - Thailandia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 7.215
Salva come PNG Salva come JPEG
Città #
Fairfield 481
Santa Clara 390
Woodbridge 329
Ashburn 297
Chandler 272
Houston 224
Shanghai 203
Seattle 201
Wilmington 169
Cambridge 167
Milan 163
Sofia 160
Serra 156
Ann Arbor 139
New York 131
Pisa 124
Boardman 108
Singapore 106
Beijing 90
Princeton 78
Abidjan 65
Florence 64
Lawrence 59
Rome 52
Dong Ket 48
Medford 47
Bremen 46
Vienna 46
Ottawa 40
Des Moines 36
London 36
Dakar 34
Hong Kong 31
Lappeenranta 31
Lucca 31
Montignoso 31
Ogden 27
Istanbul 26
Dearborn 25
Nanjing 24
Redwood City 22
Chicago 20
Naples 19
Frankfurt am Main 18
Pistoia 18
Warsaw 17
Bologna 16
Dallas 16
Livorno 15
Washington 14
Fuzhou 13
Marseille 13
San Diego 13
Kent 12
Brno 11
Guangzhou 11
Phoenix 11
Shenzhen 11
Brussels 10
Los Angeles 10
Padova 10
Izmir 9
Nanchang 9
Toronto 9
Turin 9
Wuhan 9
Changsha 8
Lancaster 8
Aguascalientes 7
Montecatini Terme 7
Palermo 7
Quanzhou 7
Ancona 6
Brescia 6
Helsinki 6
Kunming 6
Lagos 6
Munich 6
Parma 6
Redmond 6
Cascina 5
Columbus 5
Hangzhou 5
Hefei 5
Norwalk 5
Pune 5
Tagliacozzo 5
Apucarana 4
Atlanta 4
Ballabio 4
Boulder 4
Busto Arsizio 4
Haikou 4
Hebei 4
Jacksonville 4
Jiaxing 4
Nuremberg 4
Paris 4
Tianjin 4
Venice 4
Totale 5.311
Salva come PNG Salva come JPEG
Nome #
Protective Role of Flavonoids Against Colonic Motor Dysfunctions Associated with High Fat Diet-Induced Obesity 190
COMPOSTI INIBITORI DELL’INFLAMMASOMA NLRP3 E LORO USO 189
Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon 166
Pathophysiology of NSAID-associated intestinal lesions in the rat: Luminal bacteria and mucosal inflammation as targets for prevention 163
Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic 148
Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia 144
Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors 143
NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same? 142
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 140
A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation 139
Enteric protective effects of the combination Bifidobacterium longum and lactoferrin in a rat model of diclofenac-induced intestinal injury. 139
Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation 138
The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders 133
The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity 131
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 128
Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats 124
Enteric dysfunctions in experimental Parkinson's disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats 124
The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications 122
AMPK Activators as Novel Drug Candidates for the Treatment of Inflammatory Bowel Diseases 121
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? 120
High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse 117
USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation 116
Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy 116
Mechanisms underlying the non-anticoagulant effects of apixaban and dabigatran on the integrity of intestinal mucosa: a comparative pre-clinical study. 115
null 114
Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition 114
Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models 112
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease 112
Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases? 111
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 110
Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity 108
Glial A2B Adenosine Receptors Modulate Abnormal Tachykininergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity 106
null 103
Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review 101
Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity 101
Rifaximin Displays a Protective Activity in Experimental Enteropathy Induced by Indomethacin in Rats. 100
Preclinical development of fa5, a novel amp-activated protein kinase (Ampk) activator as an innovative drug for the management of bowel inflammation 98
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 97
P2X7 receptor-dependent tuning of gut epithelial responses to infection 94
Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. 94
Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy 94
Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rat 93
Donepezil improves vascular function in a mouse model of Alzheimer's disease 91
NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity 90
Protective effects of Saccharomyces boulardii CNCM I-745 Against Nonsteroidal anti-inflammatory drug-induced intestinal injury 88
Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling 83
Adenosine signaling in the tumor microenvironment 81
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology 81
Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases 79
Dietary Supplement, Containing the Dry Extract of Curcumin, Emblica and Cassia, Counteracts Intestinal Inflammation and Enteric Dysmotility Associated with Obesity 77
Neuronal regulation of intestinal immune functions in health and disease 77
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 74
Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence 67
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 66
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 66
Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship 66
- Medicament for preventing or treating irritable bowel syndrome or inflammatory bowel diseases 64
Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation 63
Intestinal epithelial barrier and neuromuscular compartment in health and disease 63
Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System? 63
From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinson's disease 63
The adenosine system at the crossroads of intestinal inflammation and neoplasia 62
Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy 57
Enteric glia at the crossroads between intestinal immune system and epithelial barrier: Implications for parkinson disease 55
The intestinal barrier in disorders of the central nervous system 49
Dietary Supplementation with the Probiotic SF68 Reinforces Intestinal Epithelial Barrier in Obese Mice by Improving Butyrate Bioavailability 49
Inflammatory Bowel Diseases: It's Time for the Adenosine System 48
Role of cyclooxygenase pathways in bowel fibrotic remodelling in a murine model of experimental colitis 47
Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches 47
NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications 45
NKG2A and COVID-19: another brick in the wall 44
Editorial: IBD Management—Novel Targets and Therapeutic Perspectives 42
Enteric Glia and Brain Astroglia: Complex Communication in Health and Disease along the Gut-Brain Axis 41
Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury 35
Glomerular hyperfiltration in morbid obesity: Role of the inflammasome signalling 34
Pharmacological modulation of P2X4 in inflammatory bowel diseases: the way towards novel therapeutics? 32
LRRK2 is reduced in Parkinson’s disease gut 32
The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis 29
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology (npj Parkinson's Disease, (2022), 8, 1, (9), 10.1038/s41531-021-00263-x) 27
Pathological Remodeling of the Gut Barrier as a Prodromal Event of High-Fat Diet-Induced Obesity 26
Velusetrag rescues GI dysfunction, gut inflammation and dysbiosis in a mouse model of Parkinson's disease 23
Gut-directed therapy in Parkinson’s disease 22
Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients 22
Adenosine signaling as target in cardiovascular pharmacology 21
LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines 20
Evaluation of the beneficial effects of a GABA-based product containing Melissa officinalis on post-inflammatory irritable bowel syndrome: a preclinical study 14
Neuromuscular Function Abnormalities 13
Are LRRK2 mysteries lurking in the gut? 13
Lactiplantibacillus plantarum HEAL9 attenuates cognitive impairment and progression of Alzheimer's disease and related bowel symptoms in SAMP8 mice by modulating microbiota-gut-inflammasome-brain axis 12
α-Synuclein in Parkinson's Disease: From Bench to Bedside 12
Gastrointestinal dysmotility in rodent models of Parkinson’s disease 12
Enteric glial NLRP3 inflammasome contributes to gut mucosal barrier alterations in a mouse model of diet-induced obesity 11
Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer’s Disease 9
Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome 8
Editorial: Reviews in neuropharmacology 2023: microbiota gut-brain axis, therapeutic insights for neurodegenerative diseases 4
The administration of Enterococcus faecium SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice 1
Totale 7.590
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020622 0 0 0 0 0 0 121 105 157 89 115 35
2020/2021765 61 61 67 32 43 33 31 53 102 119 39 124
2021/2022751 27 16 18 25 146 113 41 36 62 41 49 177
2022/20231.195 120 151 89 93 114 138 24 106 220 41 78 21
2023/20241.326 78 105 162 98 184 218 49 80 79 49 111 113
2024/20251.349 56 114 72 192 266 413 236 0 0 0 0 0
Totale 7.590